SCHEMBL1786992

SCHEMBL1786992

CCN1CCC(c2ccc(Nc3nccc(-c4c(-c5cccc(NC(=O)Cc6cccs6)c5)nc5ccccn45)n3)cc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 16/20 0.56
EGFR P00533 14/20 0.56
ERBB2 P04626 13/20 0.56
RET P07949 5/20 0.52
KDR P35968 5/20 0.52
STK3 Q13188 5/20 0.52
MAP4K5 Q9Y4K4 5/20 0.52
INSR P06213 5/20 0.52
AURKA O14965 4/20 0.52
PRKD3 O94806 4/20 0.52
MAP4K4 O95819 4/20 0.52
LCK P06239 4/20 0.52
FYN P06241 4/20 0.52
LYN P07948 4/20 0.52
FGFR1 P11362 4/20 0.52
SYK P43405 4/20 0.52
MAPK8 P45983 4/20 0.52
MAPK9 P45984 4/20 0.52
BLK P51451 4/20 0.52
NEK2 P51955 4/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1786938 0.97 IGF1R (0.59) IGF1REGFRERBB2RETKDR
SCHEMBL1790864 0.95 IGF1R (0.53) IGF1REGFRERBB2RETKDR
SCHEMBL1787302 0.92 IGF1R (0.52) IGF1REGFRERBB2RETKDR
SCHEMBL1786108 0.92 IGF1R (0.51) IGF1REGFRERBB2RETKDR
SCHEMBL1787727 0.91 IGF1R (0.51) IGF1REGFRERBB2RETKDR
SCHEMBL1790365 0.91 IGF1R (0.53) IGF1REGFRERBB2RETKDR
SCHEMBL1791901 0.90 IGF1R (0.52) IGF1REGFRERBB2RETKDR
SCHEMBL1787299 0.89 IGF1R (0.53) IGF1REGFRERBB2RETKDR
SCHEMBL1788994 0.88 IGF1R (0.72) IGF1REGFRERBB2RETKDR
SCHEMBL1790001 0.88 IGF1R (0.50) IGF1REGFRERBB2RETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US claimed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP claimed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US claimed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO claimed
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US disclosed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP disclosed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US disclosed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION PACSIN2, MAP4K2, MAP3K6 IGF1R 937/4885EGFR 1013/4885ERBB2 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.